Inoviq Ltd (AU:IIQ) has released an update.
INOVIQ Ltd announces a major leap in cancer therapy with their engineered exosomes (EEVs) achieving a 75% kill rate of breast cancer cells in vitro. Leveraging their proprietary EXO-ACE technology, the company has successfully isolated highly pure exosomes that can deliver targeted treatments, showing immense potential for metastatic breast and ovarian cancers. Moving forward, INOVIQ is set to expand their exosome production and advance towards preclinical stages, eying partnership opportunities with pharmaceutical firms.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.
